Abstract
The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Current Drug Delivery
Title:Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages
Volume: 9 Issue: 5
Author(s): V. Sankar, Parmar Nilaykumar Nareshkumar, Gohel Nishit Ajitkumar, Shalini Devi Penmetsa and Sivaram Hariharan
Affiliation:
Keywords: Drug targeting, high performance liquid chromatography, Lamivudine, Zidovudine, nanoparticles, transdermal absorption, electrically neutral polymer, physicochemical properties.
Abstract: The present study investigates the specific drug targeting of anti retroviral drugs, such as lamivudine and zidovudine, after intraperitoneal (i.p) injection by incorporation into polymeric nanoparticles (PNs) and solid lipid nanoparticles (SLNs). Our results showed that Glyceryl Monosterate-Poloxamer 188 SLNs (average diameter of 522.466 nm) showed slow drug release rates (63.18% of lamivudine and 62.37% of zidovudine were released in 12 hrs) among all the SLN formulations. For Poly lactic-co-glycolic acid (PLGA)-Poloxamer 188 PNs (average diameter of 70.348 nm), there were faster release rates of both lamivudine and zidovudine (97% and 94.06%, respectively, in 12 hrs). Tissue distribution studies were carried out in mice and concentrations of drugs in different organs were determined using high performance liquid chromatography (HPLC) after i.p. administration. Glyceryl Monosterate-Poloxamer 188 SLNs and PLGAPoloxamer 188 PNs showed increase in the distribution of lamivudine and zidovudine to liver and spleen when compared to the drugs in solution. Also, Glyceryl Monosterate-P 188 SLNs showed higher concentration of drugs in RES organs than PLGA-P 188 PNs.
Export Options
About this article
Cite this article as:
Sankar V., Nilaykumar Nareshkumar Parmar, Nishit Ajitkumar Gohel, Devi Penmetsa Shalini and Hariharan Sivaram, Comparative Studies of Lamivudine-zidovudine Nanoparticles for the Selective Uptake by Macrophages, Current Drug Delivery 2012; 9 (5) . https://dx.doi.org/10.2174/156720112802650707
DOI https://dx.doi.org/10.2174/156720112802650707 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Current Drug Targets Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
Current Diabetes Reviews Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Hierarchical Profiles of Signaling Pathways and Networks Reveal Two Complementary Pharmacological Mechanisms
CNS & Neurological Disorders - Drug Targets Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Purification and Characterization of a Lectin from the Indian Cultivar of French Bean Seeds
Protein & Peptide Letters Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Vitamin E does not Support Bone Quality in Orchidectomized Rats
Current Nutrition & Food Science The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Therapeutic Effects of Physical Exercise and the Mesenchymal Stem Cell Secretome by Modulating Neuroinflammatory Response in Multiple Sclerosis
Current Stem Cell Research & Therapy Impact of Short-Term Educational and Behavioral Therapy on Childhood Obesity
Vascular Disease Prevention (Discontinued) Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
Current Drug Therapy Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine